Ocular Therapeutix (NASDAQ:OCUL) COO Sells $51,538.90 in Stock

by · The Markets Daily

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) COO Donald Notman sold 6,035 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $8.54, for a total transaction of $51,538.90. Following the sale, the chief operating officer directly owned 377,802 shares in the company, valued at $3,226,429.08. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Donald Notman also recently made the following trade(s):

  • On Monday, February 2nd, Donald Notman sold 5,455 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.14, for a total value of $49,858.70.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock traded up $0.04 on Wednesday, reaching $8.55. The company’s stock had a trading volume of 6,694,837 shares, compared to its average volume of 5,361,677. The company has a quick ratio of 7.78, a current ratio of 7.85 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.82 billion, a P/E ratio of -5.94 and a beta of 0.90. The stock has a 50-day moving average price of $11.94 and a 200-day moving average price of $11.97. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. The firm had revenue of $14.54 million during the quarter, compared to the consensus estimate of $14.57 million. Analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 target price on shares of Ocular Therapeutix in a research report on Monday, December 8th. Wall Street Zen cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Wednesday, November 5th. HC Wainwright boosted their target price on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, TD Cowen restated a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, October 30th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.56.

Read Our Latest Stock Analysis on OCUL

Institutional Trading of Ocular Therapeutix

Hedge funds have recently made changes to their positions in the company. Pale Fire Capital SE grew its position in Ocular Therapeutix by 20.7% in the second quarter. Pale Fire Capital SE now owns 530,135 shares of the biopharmaceutical company’s stock worth $4,920,000 after acquiring an additional 90,748 shares during the period. Saturn V Capital Management LP raised its position in Ocular Therapeutix by 21.8% in the second quarter. Saturn V Capital Management LP now owns 728,576 shares of the biopharmaceutical company’s stock valued at $6,761,000 after purchasing an additional 130,385 shares during the period. Truist Financial Corp lifted its stake in shares of Ocular Therapeutix by 100.0% in the 2nd quarter. Truist Financial Corp now owns 100,000 shares of the biopharmaceutical company’s stock valued at $928,000 after purchasing an additional 50,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 893 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Ocular Therapeutix during the 2nd quarter worth about $342,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

Featured Articles